Results of voting at AGMs

Issued - Wednesday 20 May 2009, London - LSE Announcement
Voting on the resolutions put to each AGM is on a poll rather than by a show of hands. The results of the poll are announced to the London Stock Exchange, via the Regulatory Information Service, as soon as practicable after the AGM. They are also published on this page.

Results of AGM

GlaxoSmithKline (GSK) announces that at today's Annual General Meeting all resolutions, including those electing
and re-electing Board members, were passed by shareholders.

The following table shows the votes cast for each resolution:

	Resolution	Total Votes For*	%	Total Votes Against	%	Total Votes Cast	Abstentions **
1.	Adoption of Financial Statements	3,753,123,915	98.71	49,078,100	1.29	3,802,202,015	11,386,486
2.	Approval of the Remuneration Report	3,697,894,692	97.40	98,521,629	2.60	3,796,416,321	17,172,180
3.	Election of James Murdoch	3,757,009,509	99.43	21,384,326	0.57	3,778,393,835	35,194,666
4.	Re-election of Larry Culp	3,793,634,452	99.65	13,335,747	0.35	3,806,970,199	6,618,302
5.	Re-election of Sir Crispin Davis	3,792,927,536	99.63	14,128,576	0.37	3,807,056,112	6,532,389
6.	Re-election of Dr Moncef Slaoui	3,745,211,760	98.65	51,318,902	1.35	3,796,530,662	17,057,839
7.	Re-election of Dr Tom de Swaan	3,741,563,392	98.28	65,347,381	1.72	3,806,910,773	6,677,727
8.	Re-appointment of Auditors	3,737,041,438	99.50	18,663,218	0.50	3,755,704,656	57,883,845
9.	Remuneration of Auditors	3,773,188,034	99.69	11,620,178	0.31	3,784,808,212	28,780,289
10.	To authorise the company to make donations to EU Political Organisations & incur EU Political Expenditure	3,701,721,594	97.53	93,559,528	2.47	3,795,281,122	18,307,379
11.	Authority to allot shares	3,605,902,539	96.41	134,189,208	3.59	3,740,091,747	73,496,753
12.	Disapplication of pre-emption rights***	3,770,592,309	99.16	32,012,872	0.84	3,802,605,181	10,983,320
13.	Authority for the Company to purchase its own shares***	3,748,071,427	98.56	54,890,465	1.44	3,802,961,892	10,626,609
14.	Exemption from statement of senior statutory auditor's name	3,787,552,173	99.66	12,766,383	0.34	3,800,318,556	13,269,945
15.	Reduced notice of a general meeting other than an AGM***	3,669,136,339	96.39	137,612,154	3.61	3,806,748,493	6,840,007
16.	Adoption of the GSK 2009 Performance Share Plan	3,704,014,846	97.60	91,201,480	2.40	3,795,216,326	18,372,175
17.	Adoption of the GSK 2009 Share Option Plan	3,690,525,851	98.50	56,305,534	1.50	3,746,831,385	66,757,116
18.	Adoption of the GSK 2009 Deferred Annual Bonus Plan	3,721,471,866	98.00	76,062,571	2.00	3,797,534,437	16,054,064

Notes:
* Includes discretionary votes.
** A vote witheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.
*** Indicates Special Resolutions requiring a 75% majority.

The following table provides further relevant information:

	GlaxoSmithKline's Ninth AGM (2009)	GlaxoSmithKline's Eighth AGM (2008)
Issued share capital (excluding Treasury Shares)	5,188,385,638	5,352,175,102
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)	73.50%	73.78%
Total shareholder population	170,054	172,581
Total number of proxies lodged	10,580	12,896
% of shareholders who lodged proxies	6.22%	7.47%
Number of shareholders, corporate representatives and proxies who attended the AGM	276	266

S M Bicknell
Company Secretary
20 May 2009